- Home
- ALF vs MAZE Comparison
ALF vs MAZE Comparison
Compare ALF & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- MAZE
- Stock Information
- Founded
- ALF 2024
- MAZE 2018
- Country
- ALF United States
- MAZE United States
- Employees
- ALF N/A
- MAZE N/A
- Industry
- ALF
- MAZE
- Sector
- ALF
- MAZE
- Exchange
- ALF NYSE
- MAZE NYSE
- Market Cap
- ALF 379.1M
- MAZE 367.0M
- IPO Year
- ALF 2024
- MAZE 2025
- Fundamental
- Price
- ALF $10.51
- MAZE $15.24
- Analyst Decision
- ALF
- MAZE Strong Buy
- Analyst Count
- ALF 0
- MAZE 4
- Target Price
- ALF N/A
- MAZE $23.50
- AVG Volume (30 Days)
- ALF 74.7K
- MAZE 125.7K
- Earning Date
- ALF 01-01-0001
- MAZE 08-14-2025
- Dividend Yield
- ALF N/A
- MAZE N/A
- EPS Growth
- ALF N/A
- MAZE N/A
- EPS
- ALF 0.37
- MAZE 0.34
- Revenue
- ALF N/A
- MAZE $167,500,000.00
- Revenue This Year
- ALF N/A
- MAZE N/A
- Revenue Next Year
- ALF N/A
- MAZE N/A
- P/E Ratio
- ALF $28.31
- MAZE $44.89
- Revenue Growth
- ALF N/A
- MAZE N/A
- 52 Week Low
- ALF $9.96
- MAZE $6.71
- 52 Week High
- ALF $10.64
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- MAZE N/A
- Support Level
- ALF N/A
- MAZE N/A
- Resistance Level
- ALF N/A
- MAZE N/A
- Average True Range (ATR)
- ALF 0.00
- MAZE 0.00
- MACD
- ALF 0.00
- MAZE 0.00
- Stochastic Oscillator
- ALF 0.00
- MAZE 0.00
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.